Your session is about to expire
← Back to Search
Intermittent letrozole therapy for Breast Cancer
Summary
The purpose of this research study is to study the effects of using aromatase inhibitor (AI) therapy intermittently on participants with breast cancer. AIs are a class of drugs used to treat breast cancer in postmenopausal women. They work by decreasing the level of estrogen, which is believed to stimulate the growth of tumor tissue. Breast cancer that progresses despite therapy with an AI is thought to have become resistant to AI therapy. There is scientific evidence to suggest that resistant breast cancer cells learn to grow at the very low levels of estrogen present on AI therapy, and that increasing estrogen levels even slightly by stopping AI therapy may inhibit the breast cancer cells.
- Breast Cancer
Timeline
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 79 Patients • NCT02137538Trial Design
Find a Location
Who is running the clinical trial?
Share this study with friends
Copy Link
Messenger